Brighthouse Financial Trades Below 50-Day SMA: How to Play the Stock?

Brighthouse Financial (BHF) exhibits a mixed financial profile, with shares trading below the 50-day SMA and at a significant discount (P/B 0.47x vs. industry 1.87x). While the company shows operational strength through robust annuity sales, up 8.4% to $2.6 billion in Q2 2025, and improving life insurance momentum, these gains are substantially offset by severe financial headwinds, including a 68% surge in H1 2025 expenses to $3.5 billion, a fivefold increase in debt over five years to $3.2 billion, negative net margins, and a low 0.5% return on invested capital. Despite these challenges, analysts project a 23.4% upside from the current price, indicating a complex investment case balancing operational growth against significant financial inefficiencies and leverage.

Analysis

Brighthouse Financial (BHF) presents a complex investment case, characterized by a stark contrast between operational growth and severe financial strain. On one hand, the company demonstrates solid business momentum, with annuity sales increasing 8.4% year-over-year to $2.6 billion in the second quarter of 2025 and life insurance sales rising 17.8% sequentially. This is supported by an improving adjusted net investment income yield, which reached 4.27% in the first half of 2025. However, these operational positives are overshadowed by significant financial headwinds. Total expenses surged 68% to $3.5 billion in the first half of 2025, driving the net margin to negative 6%. The balance sheet is heavily leveraged, with total debt increasing fivefold over five years to $3.2 billion, resulting in a debt-to-equity ratio of 55%, far exceeding the industry average of 16.7%. Capital efficiency is also weak, with a return on invested capital of just 0.5%. The market appears to be pricing in these risks, as the stock trades below its 50-day SMA and has underperformed its industry year-to-date, despite its deeply discounted valuation at a 0.47x price-to-book ratio. While analysts project a 23.4% upside to an average price target of $56.90, near-term earnings estimates for 2025 have recently been revised downward, reflecting the prevailing uncertainty.

Key Decisions for Investors

• Investors should weigh the deeply discounted valuation (0.47x P/B) and significant analyst price target upside against the substantial balance sheet risk, including a 55% debt-to-equity ratio and surging expenses.
• Monitor key performance indicators for margin stabilization and expense control, as the 68% surge in H1 expenses is a primary concern that must be addressed to unlock shareholder value.
• Given the conflicting signals of strong product sales versus weak profitability and high leverage, a neutral stance may be prudent until the company demonstrates a clear path to improving its negative net margin and inefficient 0.5% return on invested capital.
• For those considering a position, the stock's performance below its 50-day moving average suggests waiting for technical confirmation of a trend reversal before committing capital.